Skip to main content

Becton Dickinson and Company(BDX-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

BD Receives 510(k) Clearance for COVID-19, Influenza A/B, RSV Molecular Combination Test

PR Newswire - Tue Aug 1, 2023

Single Test on BD MAX™ System Identifies and Differentiates Multiple Respiratory Infectious Diseases from One Sample

FRANKLIN LAKES, N.J., Aug. 1, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the BD Respiratory Viral Panel (RVP) for BD MAX™ System, a single molecular diagnostic combination test that identifies and distinguishes SARS-CoV-2, influenza A, influenza B, and Respiratory Syncytial Virus (RSV) in approximately two hours.

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe